17:29:56 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Eastwood Bio-Medical Canada Inc
Symbol EBM
Shares Issued 68,885,969
Close 2026-11-16 C$ 1.75
Market Cap C$ 120,550,446
Recent Sedar+ Documents

Eastwood amends FY 2025, Q3 FY 2026 results

2026-11-16 17:00 ET - News Release

Subject: Eastwood Bio-Medical Canada Inc. - News Release for Dissemination PDF Document

File: Attachment News Release - Refile MD&A.pdf

EASTWOOD BIO-MEDICAL CANADA INC.

NEWS RELEASE

Eastwood Bio-Medical Canada Inc. Announces Refiling of its Annual and Interim MD&A

November 16, 2026 Richmond, British Columbia Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the "Company") announces that as a result of a review by the British Columbia Securities Commission (the "BCSC"), the Company is issuing this press release to clarify its disclosure.

With respect to the Company's annual management's discussion and analysis for the year ended October 31, 2025 (the "Annual MD&A") and its interim management's discussion and analysis for the nine month period ended July 31, 2026 (the "Interim MD&A", and together with the Annual MD&A, the "Affected Filings"), the BCSC has concluded that the Affected Filings lack sufficient discussion as per the requirements of Form 51-102F1. As a result, the Company has amended and refiled the Affected Filings.

The Affected Filings clarify the Company's supply and manufacturing arrangements, expand the disclosure of related-party relationships and balances, and strengthen the discussion of liquidity and financing needs. They also provide more detail on the factors affecting revenue and gross margin, add disclosure of recent strategic agreements, and make minor corrections and formatting updates throughout.

The amended and restated Affected Filings have been filed on SEDAR+ at www.sedarplus.ca. The amended and restated Affected Filings replace and supersede the corresponding financial statements and MD&A previously filed by the Company. Readers should rely only on the amended and restated Affected Filings now available on SEDAR+.

For further information, please contact:

Eastwood Bio-Medical Canada Inc. Yunji Kim, President and Chief Financial Officer. Telephone: (604) 247-2100

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Word Document

File: '\\swfile\EmailIn\20261116 135402 Attachment News Release - Refile MD&A.docx'

© 2026 Canjex Publishing Ltd. All rights reserved.